Resource Summary Report

Generated by RRID on Aug 31, 2026

MDA-MB-453

RRID:CVCL_0418
Type: Cell Line

Proper Citation

RRID:CVCL_0418

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0418

Proper Citation: RRID:CVCL_0418

Description: Cell line MDA-MB-453 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast adenocarcinoma

Defining Citation: PMID:730202, PMID:1961733, PMID:3518877, PMID:9671407, PMID:9815641, PMID:10969801, PMID:11687795, PMID:11789735, PMID:12353263, PMID:12800145, PMID:16142302, PMID:16397213, PMID:16541312, PMID:17157791, PMID:18516279, PMID:19582160, PMID:19593635, PMID:20164919, PMID:20215515, PMID:21378333, PMID:22121396, PMID:22414580, PMID:22460905, PMID:22585861, PMID:22719059, PMID:23601657, PMID:24094812, PMID:24176112, PMID:25485619, PMID:25877200, PMID:25892236, PMID:25984343, PMID:26218769, PMID:26589293, PMID:27397505, PMID:28196595, PMID:28889351, PMID:30787054, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDA-MB-453

Synonyms: MDA-MB 453, MDA MB 453, MDA-MB453, MDAMB453, MDA-453, MDA453, MD Anderson-Metastatic Breast-453

Cross References: BTO:BTO_0001908, CLO:CLO_0007640, CLO:CLO_0050867, EFO:EFO_0001215, MCCL:MCC:0000315, CLDB:cl3411, CLDB:cl7187, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:HTB-131, BCRC:60429, BioGRID_ORCS_Cell_line:552, BioSample:SAMN01821576, BioSample:SAMN01821647, BioSample:SAMN03472899, BioSample:SAMN10988263, cancercelllines:CVCL_0418, CCRID:1101HUM-PUMC000016, CCRID:3101HUMSCSP5044, CCRID:3101HUMTCHu233, Cell_Model_Passport:SIDM00272, ChEMBL-Cells:CHEMBL3307596, ChEMBL-Targets:CHEMBL614334, CLS:305042, Cosmic:687497, Cosmic:871157, Cosmic:897426, Cosmic:904383, Cosmic:908122, Cosmic:923060, Cosmic:934529, Cosmic:979712, Cosmic:991326, Cosmic:997920, Cosmic:1010927, Cosmic:1018468, Cosmic:1027056, Cosmic:1044223, Cosmic:1046931, Cosmic:1047694, Cosmic:1129656, Cosmic:1136356, Cosmic:1152522, Cosmic:1176651, Cosmic:1287911, Cosmic:1289401, Cosmic:1308995, Cosmic:1434956, Cosmic:1524345, Cosmic:1601924, Cosmic:1603222, Cosmic:1609457, Cosmic:2165012, Cosmic:2301532, Cosmic:2318375, Cosmic:2564832, Cosmic:2820307, Cosmic-CLP:908122, DepMap:ACH-000910, DSMZ:ACC-65, DSMZCellDive:ACC-65, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, FANTOM5_SSTAR:10419-106C5, GDSC:908122, GEO:GSM813, GEO:GSM115117, GEO:GSM217590, GEO:GSM219956, GEO:GSM274656, GEO:GSM344355, GEO:GSM344405, GEO:GSM350530, GEO:GSM421879, GEO:GSM481307, GEO:GSM783928, GEO:GSM844602, GEO:GSM847417, GEO:GSM887300, GEO:GSM888375, GEO:GSM1008910, GEO:GSM1053710, GEO:GSM1172983, GEO:GSM1264071, GEO:GSM1264075, GEO:GSM1264113, GEO:GSM1264117, GEO:GSM1374660, GEO:GSM1374661, GEO:GSM1374662, GEO:GSM1384316, GEO:GSM1401667, GEO:GSM1421431, GEO:GSM1661983, GEO:GSM1664568, GEO:GSM1670086, IARC_TP53:762, IARC_TP53:21146, IARC_TP53:26995, ICLC:HTL01013, IGRhCellID:MDAMB453, IZSLER:BS TCL 247, KCLB:30131, LiGeA:CCLE_768, LINCS_HMS:50334, LINCS_LDP:LCL-1485, Lonza:837, NCBI_Iran:C214, PharmacoDB:MDAMB453_906_2019, PRIDE:PXD000309, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_0418, PubChem_Cell_line:CVCL_0418, RCB:RCB1192, SLKBase:3613, Wikidata:Q54904642

ID: CVCL_0418

Record Creation Time: 20220427T220756+0000

Record Last Update: 20260829T234602+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-453.

No alerts have been found for MDA-MB-453.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 1504 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Wang J, et al. (2026) Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers. Cell reports. Medicine, 7(2), 102577.

Kopp A, et al. (2026) In Vivo Auto-tuning of Antibody-Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies. Molecular cancer therapeutics, 25(4), 610.

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. Cancer research, 86(6), 1467.

Ohashi T, et al. (2026) ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer research communications, 6(2), 421.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. Cell reports. Medicine, 7(7), 102922.

Wang H, et al. (2026) ZNF296 Drives Immune Evasion in Epithelial Cancers by Repressing Immune Stimulatory Genes. Cancer research, 86(1), 116.

Sun Y, et al. (2026) CircNSD2 promotes metastasis and immune escape by increasing the USP10/SRSF6-mediated alternative splicing of TPM1 in TNBC. Molecular cancer, 25(1).

Rad SK, et al. (2026) eFluor 450 Enables Superior Detection of Intracellular Staphylococcus aureus in High-Autofluorescence Triple-Negative Breast Cancer Cells. Cytometry. Part A : the journal of the International Society for Analytical Cytology, 109(2), 135.

Wang Z, et al. (2026) RAD51 succinylation regulates homologous recombination and contributes to the chemosensitivity in cancer. Molecular cell, 86(4), 585.

Li K, et al. (2026) The GATA3-RFPL3-ASK1 axis suppresses breast cancer growth and lung metastasis. Apoptosis : an international journal on programmed cell death, 31(4).

Qasem H, et al. (2026) Cell-Penetrating Peptide-Mediated siRNA Targeting of LDHC Suppresses Tumor Growth in a Triple-Negative Breast Cancer Zebrafish Xenograft Model. Pharmaceutics, 18(1).

Christenson JL, et al. (2026) Metastasis-Associated Wound Repair Promotes Reciprocal Lung Epithelium Activation and Breast Cancer Metastatic Outgrowth. Cancer research communications, 6(4), 750.

Matsuura K, et al. (2026) Distinct metabolic dependency on BCAA defines cancer stemness and malignancy in human triple-negative breast cancer. Cell reports, 45(7), 117630.

McBean B, et al. (2026) Transcriptomic analysis to uncover the mechanism of radiosensitization of AR-positive triple-negative breast cancers with AR inhibition. NPJ breast cancer, 12(1).

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell, 189(10), 2898.

Ishida M, et al. (2026) AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. NPJ precision oncology, 10(1).

Cheng TC, et al. (2025) Fibroblast growth factor receptor four inhibitor FGF401 improves the efficacy of trastuzumab in FGFR4-overexpressing breast cancer cells. International journal of cancer, 156(8), 1606.

Smoak CN, et al. (2025) ZYS-1 is not an ADAR1 inhibitor. RNA (New York, N.Y.), 31(12), 1703.

Harper NW, et al. (2025) RNA Pol II inhibition activates cell death independently from the loss of transcription. Cell.

Nath S, et al. (2025) Unlocking the therapeutic potential of rigosertib as a selective therapy for ovarian cancer. Cell reports. Medicine, 6(7), 102218.